<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">periodontology</journal-id><journal-title-group><journal-title xml:lang="ru">Пародонтология</journal-title><trans-title-group xml:lang="en"><trans-title>Parodontologiya</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1683-3759</issn><issn pub-type="epub">1726-7269</issn><publisher><publisher-name>Russian Periodontal Association (RPA)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33925/1683-3759-2021-26-4-284-288</article-id><article-id custom-type="elpub" pub-id-type="custom">periodontology-566</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОР</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW</subject></subj-group></article-categories><title-group><article-title>Биомаркеры костной регенерации в челюстно-лицевой хирургии: критический обзор литературы</article-title><trans-title-group xml:lang="en"><trans-title>Bone regeneration biomarkers in maxillofacial surgery: a critical review of literature</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1135-4678</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Косач</surname><given-names>Г. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kosach</surname><given-names>G. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Косач Герман Александрович, аспирант кафедры стоматологии хирургической и челюстно-лицевой хирургии</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>German A. Kosach, DMD, PhD student, Department of Oral and Maxillofacial Surgery</p><p>Saint Petersburg</p></bio><email xlink:type="simple">german1kosach@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2221-4088</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кутукова</surname><given-names>С. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kutukova</surname><given-names>S. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кутукова Светлана Игоревна, кандидат медицинских наук, доцент кафедры стоматологии хирургической и челюстно-лицевой хирургии</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Svetlana I. Kutukova, DMD, PhD, Associate Professor, Department of Oral and Maxillofacial Surgery</p><p>Saint Petersburg</p></bio><email xlink:type="simple">dr.s.kutukova@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6951-7599</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Власов</surname><given-names>Т. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Vlasov</surname><given-names>T. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Власов Тимур Дмитриевич, доктор медицинских наук, профессор, заведующий кафедрой патофизиологии с курсом клинической патофизиологии</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Timur D. Vlasov, DMD, PhD, DSc, Professor, Head of the Department of Pathophysiology with the Course of  Clinical Pathophysiology</p><p>Saint Petersburg</p></bio><email xlink:type="simple">tvlasov@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7700-7724</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яременко</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Yaremenko</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Яременко Андрей Ильич, доктор медицинских наук, профессор, заведующий кафедры стоматологии хирургической и ЧЛХ, президент Стоматологической ассоциации Санкт-Петербурга, вице-президент Стоматологической ассоциации России</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Andrei I. Yaremenko, DMD, PhD, DSc, Professor, Head of the Department of Oral and Maxillofacial Surgery</p><p>Saint Petersburg</p></bio><email xlink:type="simple">ayaremenko@me.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Первый Санкт-Петербургский государственный медицинский университет имени акад. И.П. Павлова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>First Pavlov State Medical University of St. Peterburg</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Первый Санкт-Петербургский государственный медицинский университет имени акад. И.П. Павлова; Городской клинический онкологический диспансер</institution><country>Россия</country></aff><aff xml:lang="en"><institution>First Pavlov State Medical University of St. Peterburg; City Clinical Oncology Dispensary</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>20</day><month>01</month><year>2022</year></pub-date><volume>26</volume><issue>4</issue><fpage>284</fpage><lpage>288</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Косач Г.А., Кутукова С.И., Власов Т.Д., Яременко А.И., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Косач Г.А., Кутукова С.И., Власов Т.Д., Яременко А.И.</copyright-holder><copyright-holder xml:lang="en">Kosach G.A., Kutukova S.I., Vlasov T.D., Yaremenko A.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.parodont.ru/jour/article/view/566">https://www.parodont.ru/jour/article/view/566</self-uri><abstract><p>Актуальность. Известно, что при возникновении медикаментозно-ассоциированного остеонекроза возникает ряд патологических изменений. Таким изменениям подвергаются и титры биомаркеров, отвечающих за метаболизм костной ткани. Они важны в диагностике и планировании лечения пациентов, в особенности при оперативных вмешательствах, в виду риска возникновения остеонекроза. Цель – на основании данных современной научной литературы и статей выявить маркеры нарушения костного ремоделирования и эндотелия, имеющие наибольшие значения для оптимизации ранней диагностики нарушения микроциркуляции у пациентов с челюстно-лицевыми патологиями.Материалы и методы. Обзор имеющихся данных в литературе по нормальной анатомии кости, биомаркерам костной ткани и регулирующих факторов. Изучение режимов диагностики и выявление наиболее ценных и быстрых в нарушении кости и эндотелия сосудов.Результаты. По результатам исследований остеокальцин, С-концевой телопептид и тартрат-резистентная кислая фосфатаза, VEGF являются наиболее информативными в клинической практике при прогнозировании возникновения остеонекроза челюстных костей. При концентрации С-концевого телопептида в сыворотке меньше 100 pg/mL увеличивается риск появления остеонекроза. Сывороточный остеокальцин считается специфическим биомаркером функции остеобластов для оценки скорости образования костной ткани при остеопорозе. Средний уровень остеокальцина выявил значительную разницу между постменопаузальным остеопорозом (16,16 ± 4,5 нг/мл) и неостеопорозом (11,26 ± 3,07 нг/мл) у женщин. Тартрат-резистентная кислая фосфатаза (TRAP 5b) используется в качестве эталона активности и количества остеокластов. TRAP 5b может быть специфически обнаружен в сыворотке с помощью иммуноанализов.Заключение. Исследование маркеров перерождения костной ткани и сосудистых маркеров позволяет более ясно понять принципы возникновения остеонекроза и, следовательно, более четко прогнозировать, диагностировать остеонекроз, а также грамотно подбирать тактику лечения данных пациентов, вид оперативного вмешательства: консервативное, оперативное (частичная резекция, полная резекция челюстей), паллиативное, пре- и постмедикаментозную подготовку организма к вмешательству.</p></abstract><trans-abstract xml:lang="en"><p>Relevance. Drug-associated osteonecrosis is known to cause some pathological changes. The titers of biomarkers responsible for bone metabolism are also subject to such changes. They are essential in the diagnosis and treatment planning, especially during surgical interventions, because of the risk of osteonecrosis. Purpose – based on the data of modern scientific literature and articles, identifying markers of bone remodeling and endothelial disorders is of primary importance for optimizing the early diagnosis of microcirculati on disorders in patients with maxillofacial pathologies.Materials and methods. A review of available data in the literature on normal bone anatomy, bone biomarkers, and regulatory factors. The study of diagnostic modes and identification of the most valuable and fastest in bone and vascular endothelium impairment.Results. According to the studies, osteocalcin, C-terminal telopeptide, tartrate-resistant acid phosphatase and VEGF are clinically the most informative for predicting jawbone osteonecrosis. With a serum C-terminal telopeptide concentration of less than 100 pg/mL, the risk of osteonecrosis increases. Serum osteocalcin is a specific biomarker of osteoblast function for assessing the rate of bone formation in osteoporosis. The average osteocalcin level revealed a significant difference between postmenopausal osteoporotic (16.16 ± 4.5 ng/ml) and non-osteoporotic (11.26 ± 3.07 ng/ml) women. Tartrate-resistant acid phosphatase (TRAP 5b) is used to reference the activity and number of osteoclasts. TRAP 5b can be specifically detected in serum by immunoassays.Conclusion. The study of bone degeneration markers and vascular markers allows us to understand the principles of the occurrence of osteonecrosis more clearly, and, therefore, more clearly predict, diagnose osteonecrosis, and also correctly select the tactics of treatment for these patients, the type of surgical intervention, conservative, operative (partial resection, total jaw resection), – palliative, pre- and post-drug preparation of the body for intervention.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>биомаркеры костной резорбции</kwd><kwd>остеонекроз челюстей</kwd><kwd>лабораторная диагностика</kwd><kwd>остеокальцин</kwd><kwd>С-концевой телопептид</kwd><kwd>тартрат-устойчивая фосфатаза</kwd></kwd-group><kwd-group xml:lang="en"><kwd>bone resorption biomarkers</kwd><kwd>jaw osteonecrosis</kwd><kwd>laboratory diagnosis</kwd><kwd>osteocalcin</kwd><kwd>C-terminal telopeptide</kwd><kwd>tartrate-resistant phosphatase</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Marx RE, et al. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. Journal of oral and maxillofacial surgery: official journal of the American Association of Oral and Maxillofacial Surgeons. 2007. 65(12):2397-410 doi: 10.1016/j.joms.2007.08.003</mixed-citation><mixed-citation xml:lang="en">Marx RE, et al. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. Journal of oral and maxillofacial surgery: official journal of the American Association of Oral and Maxillofacial Surgeons. 2007. 65(12):2397-410 doi: 10.1016/j.joms.2007.08.003</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Sales Lima MV1 de, et al. Denosumab Related Osteonecrosis of Jaw: a Case Report. Journal of Oral and Maxillofacial Research. 2018;Dec;30;9(4):e5. doi: 10.5037/jomr.2018.9405</mixed-citation><mixed-citation xml:lang="en">Sales Lima MV1 de, et al. Denosumab Related Osteonecrosis of Jaw: a Case Report. Journal of Oral and Maxillofacial Research. 2018;Dec;30;9(4):e5. doi: 10.5037/jomr.2018.9405</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Mawardi H, et al. Osteonecrosis of the jaw associated with ziv-aflibercept. Journal of Gastrointestinal Oncology. 2016 Dec;7(6):E81-E87. doi: 10.21037/jgo.2016.05.07</mixed-citation><mixed-citation xml:lang="en">Mawardi H, et al. Osteonecrosis of the jaw associated with ziv-aflibercept. Journal of Gastrointestinal Oncology. 2016 Dec;7(6):E81-E87. doi: 10.21037/jgo.2016.05.07</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Harold N Rosen. Use of biochemical markers of bone turnover in osteoporosis. Clinical Chemistry and Laboratory Medicine. 2008;46(10):1345-57. doi: 10.1515/CCLM.2008.310</mixed-citation><mixed-citation xml:lang="en">Harold N Rosen. Use of biochemical markers of bone turnover in osteoporosis. Clinical Chemistry and Laboratory Medicine. 2008;46(10):1345-57. doi: 10.1515/CCLM.2008.310</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Del Fattore, Andrea, Anna Teti, and Nadia Rucci. Osteoclast receptors and signaling. Archives of biochemistry and biophysics. 2008;473(2):147-60. doi: 10.1016/j.abb.2008.01.011</mixed-citation><mixed-citation xml:lang="en">Del Fattore, Andrea, Anna Teti, and Nadia Rucci. Osteoclast receptors and signaling. Archives of biochemistry and biophysics. 2008;473(2):147-60. doi: 10.1016/j.abb.2008.01.011</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Chen X, et al. Osteoblast–osteoclast interactions. Connective tissue research. 2018;59(2):99-107. doi: 10.1080/03008207.2017.1290085</mixed-citation><mixed-citation xml:lang="en">Chen X, et al. Osteoblast–osteoclast interactions. Connective tissue research. 2018;59(2):99-107. doi: 10.1080/03008207.2017.1290085</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kathryn L, ed. Pathophysiology: The Biologic Basis for Disease in Adults and Children. 8 edition. 2019. Available from: https://vk.com/doc313186384_520259268?hash=08f64af1b82bfc6a95&amp;dl=c27e5d0e4f93077aa1</mixed-citation><mixed-citation xml:lang="en">Kathryn L, ed. Pathophysiology: The Biologic Basis for Disease in Adults and Children. 8 edition. 2019. Available from: https://vk.com/doc313186384_520259268?hash=08f64af1b82bfc6a95&amp;dl=c27e5d0e4f93077aa1</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Brad W.Neville, et al. Periodontal Pathology, in Color Atlas of Oral and Maxillofacial Diseases. 2019;93-107. https://doi.org/10.1016/B978-0-323-55225-7.00004-X</mixed-citation><mixed-citation xml:lang="en">Brad W.Neville, et al. Periodontal Pathology, in Color Atlas of Oral and Maxillofacial Diseases. 2019;93-107. https://doi.org/10.1016/B978-0-323-55225-7.00004-X</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. Journal of oral and maxillofacial surgery: official journal of the American Association of Oral and Maxillofacial Surgeons. 2003;61(9):1115-7. doi: 10.1016/S0278-2391(03)00720-1</mixed-citation><mixed-citation xml:lang="en">Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. Journal of oral and maxillofacial surgery: official journal of the American Association of Oral and Maxillofacial Surgeons. 2003;61(9):1115-7. doi: 10.1016/S0278-2391(03)00720-1</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ruggiero SL et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. Journal of oral and maxillofacial surgery: official journal of the American Association of Oral and Maxillofacial Surgeons. 2014;Oct;72(10):1938-56. doi: 10.1016/j.joms.2014.08.017</mixed-citation><mixed-citation xml:lang="en">Ruggiero SL et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. Journal of oral and maxillofacial surgery: official journal of the American Association of Oral and Maxillofacial Surgeons. 2014;Oct;72(10):1938-56. doi: 10.1016/j.joms.2014.08.017</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
